Terns Pharmaceuticals, Inc. ROA

ROA of TERN for past 10 years: annual, quarterly and twelve month trailing (TTM) including ROA growth rates and interactive chart. Return on Assets (ROA) is an indicator of how well a company utilizes its assets, by determining how profitable a company is relative to its total assets. A company with $1 million in net income and $10 million in average assets will have a 10% ROA.

Highlights and Quick Summary

  • Annual ROA for 2021 was -38.53% (a -23.73% decrease from previous year)
  • Annual ROA for 2020 was -50.52% (a -58.41% decrease from previous year)
  • Annual ROA for 2019 was -121.46% (a 287.43% increase from previous year)
  • Twelve month ROA ending March 31, 2022 was -28.43% (a -26.21% decrease compared to previous quarter)
  • Twelve month trailing ROA decreased by -23.06% year-over-year
Trailing ROA for the last four month:
31 Mar '22 31 Dec '21 30 Sep '21 30 Jun '21
-28.43% -38.53% -39.07% -36.95%
Visit stockrow.com/TERN for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical ROA of Terns Pharmaceuticals, Inc.

Most recent ROAof TERN including historical data for past 10 years.

Interactive Chart of ROA of Terns Pharmaceuticals, Inc.

Terns Pharmaceuticals, Inc. ROA for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 -38.53%
2020 -50.52%
2019 -121.46%
2018 -31.35%

Business Profile of Terns Pharmaceuticals, Inc.

Sector: Healthcare
Industry: Biotechnology
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical trial for the treatment of NASH; and TERN-201, a vascular adhesion protein-1 inhibitor that is in Phase Ib clinical trial for the treatment of NASH. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase I clinical trial for the treatment of NASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for NASH and metabolic diseases, such as obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.